

**ASX ANNOUNCEMENT**

**CELLMID CAPITAL STRUCTURE POST 20:1 CONSOLIDATION**

**SYDNEY: Tuesday, 5 December 2017**, Cellmid Limited (ASX: CDY) advises that, following shareholder approval of the 20:1 consolidation of the Company's securities on 23 November 2017, the capital structure of the Company is as follows:

<b>ASX</b>	<b>DESCRIPTION</b>	<b>NUMBER</b>
CDY	ORDINARY FULLY PAID SHARES	53,422,884
N/A	UNLISTED OPTIONS	1,650,000

The last day to register the Company's securities on a post-reorganised basis is today; Tuesday, 5 December 2017. Trading will commence on a normal T+2 basis on Wednesday, 6 December 2017. This means that the first settlement of trades conducted on a normal T+2 basis is Friday, 8 December 2017.

End

Contact: Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan and the USA and currently expanding distribution in other territories. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

For personal use only